PE20181296A1 - Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona para el tratamiento de la enfermedad de parkinson - Google Patents

Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona para el tratamiento de la enfermedad de parkinson

Info

Publication number
PE20181296A1
PE20181296A1 PE2018000570A PE2018000570A PE20181296A1 PE 20181296 A1 PE20181296 A1 PE 20181296A1 PE 2018000570 A PE2018000570 A PE 2018000570A PE 2018000570 A PE2018000570 A PE 2018000570A PE 20181296 A1 PE20181296 A1 PE 20181296A1
Authority
PE
Peru
Prior art keywords
disease
crystalline form
dihydroisoquinolin
ethanone
dichlorophenyl
Prior art date
Application number
PE2018000570A
Other languages
English (en)
Inventor
Gregory Alan Stephenson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20181296A1 publication Critical patent/PE20181296A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se refiere a una forma cristalina de 2-(2,6-diclorofenil)-1-[(1S,3R)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1H)-il]etanona y composiciones farmaceuticas que comprenden a dicha forma cristalina. Dichos compuestos son moduladores alostericos positivos (MAP) del receptor de dopamina 1 (D1) y son utiles para el tratamiento de la enfermedad de Alzheimer, Parkinson, entre otros
PE2018000570A 2015-10-23 2016-10-18 Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona para el tratamiento de la enfermedad de parkinson PE20181296A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562245391P 2015-10-23 2015-10-23

Publications (1)

Publication Number Publication Date
PE20181296A1 true PE20181296A1 (es) 2018-08-07

Family

ID=57233858

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000570A PE20181296A1 (es) 2015-10-23 2016-10-18 Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona para el tratamiento de la enfermedad de parkinson

Country Status (13)

Country Link
CN (1) CN108137506A (es)
AR (1) AR106332A1 (es)
AU (1) AU2016341115A1 (es)
CA (1) CA2999332A1 (es)
DO (1) DOP2018000103A (es)
EA (1) EA201890525A1 (es)
EC (1) ECSP18030976A (es)
IL (1) IL257872A (es)
MX (1) MX2018004794A (es)
PE (1) PE20181296A1 (es)
PH (1) PH12018500859A1 (es)
TW (1) TW201725199A (es)
WO (1) WO2017070068A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI725408B (zh) * 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑
JP2022514659A (ja) * 2018-12-18 2022-02-14 イーライ リリー アンド カンパニー ドーパミン作動性ｃｎｓ障害の治療におけるｌｙ３１５４２０７の使用のための用量レジメン
TWI825323B (zh) * 2019-06-18 2023-12-11 美商美國禮來大藥廠 用於製備2-(2,6-二氯苯基)-1-[(1s,3r)-3-(羥甲基)-5-(3-羥基-3-甲基丁基)-1-甲基-3,4-二氫異喹啉-2(1h)-基]乙烯酮之方法及中間物
WO2022192231A1 (en) 2021-03-08 2022-09-15 Eli Lilly And Company Use of mevidalen and other d1 positive allosteric modulators in the treatment of hallucinations and dementia-related psychosis
EP4304577A1 (en) 2021-03-09 2024-01-17 Eli Lilly And Co. Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression
CN113264926A (zh) * 2021-05-31 2021-08-17 东北林业大学 一种牡荆素与利血平的共晶及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236934A (en) * 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
BRPI0808525A2 (pt) * 2007-03-01 2014-08-19 Janssen Pharmaceutica Nv Compostos de tetraidroisoquinolina como moduladors do receptor de histamina h3
US20120252853A1 (en) * 2011-04-01 2012-10-04 H. Lundbeck A/S Positive allosteric modulators of nicotinic acetylcholine receptor
JO3316B1 (ar) * 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل

Also Published As

Publication number Publication date
TW201725199A (zh) 2017-07-16
AR106332A1 (es) 2018-01-03
CN108137506A (zh) 2018-06-08
WO2017070068A1 (en) 2017-04-27
DOP2018000103A (es) 2018-10-31
CA2999332A1 (en) 2017-04-27
AU2016341115A1 (en) 2018-04-12
ECSP18030976A (es) 2018-05-31
MX2018004794A (es) 2018-06-19
IL257872A (en) 2018-06-03
EA201890525A1 (ru) 2018-09-28
PH12018500859A1 (en) 2018-10-29

Similar Documents

Publication Publication Date Title
PE20181296A1 (es) Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona para el tratamiento de la enfermedad de parkinson
CL2016002812A1 (es) Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación.
CL2019001978A1 (es) Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo.
PE20180501A1 (es) Lactamas biciclicas y metodos de uso de las mismas
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
PE20152032A1 (es) Compuestos de 3,4-dihidroisoquinolin-2(1h)-il
CL2015000578A1 (es) Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer.
JP2014221779A5 (es)
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201691853A1 (ru) Агонисты мускариновых рецепторов
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
PE20141200A1 (es) Formulacion de una capsula que comprende montelukast y levocetirizina
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
CL2015003195A1 (es) Derivados de purina como agonistas del receptor cb2.
CL2015003196A1 (es) Derivados de pirrolo[2,3-d]pirimidina como agonistas del receptor cb2.
EA201691160A1 (ru) Антагонисты s1p3
EA201591649A1 (ru) Составы с органическими соединениями
CL2020000601A1 (es) Composición farmacéutica.
EA201892341A1 (ru) Полиморфные формы 3-[2-бутил-1-(2-диэтиламиноэтил)-1h-бензоимидазол-5-ил]-n-гидроксиакриламида и их применение
CO2017007691A2 (es) Inhibidores de la β-secretasa derivados de la 5-amino-3-(5-(3-isoxazol-5-il)-3-(fluorometil)-6,6-dimetil-1-(metilimino)-3,6-dihidro-2h-1,4-tiazina o 5-amino-3-(5-(1h-1,2,3-triazol-4-il)-2-fluorofenil)-6,6-dimetil-1-(metilimino)-3,6-dihidro-2h-1,4-tiazina composiciones que los comprenden y métodos de elaboración
PE20190382A1 (es) Derivados etinilo
EA201792558A1 (ru) Противогрибковый 4-(4-(4-(((3r,5r)-5-((1h-1,2,4-триазол-1-ил)метил)-5-(2,4-дифторфенил)тетрагидрофуран-3-ил)метокси)-3-метилфенил)пиперазин-1-ил)-n-(2-гидроксициклогексил)бензамид или его фармацевтически приемлемая соль
BR112016029604A2 (pt) ?sais farmaceuticamente aceitáveis, forma cristalina, padrão cristalino, composições farmacêuticas, sais de glucamina, utilização de um sal e de uma composição farmacêutica, método para o tratamento do câncer e composto para a utilização?
PE20170926A1 (es) Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson
CL2015002188A1 (es) Agentes analgésicos oculares tópicos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal